Ibrexafungerp: A novel oral glucan synthase inhibitor

M. R. Davis, M. A. Donnelley, G. R. Thompson

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations


Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.

Original languageEnglish (US)
Pages (from-to)579-592
Number of pages14
JournalMedical mycology
Issue number5
StatePublished - Nov 23 2019
Externally publishedYes


  • antifungal
  • aspergillosis
  • candidiasis
  • in vitro activity
  • in vivo studies

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Ibrexafungerp: A novel oral glucan synthase inhibitor'. Together they form a unique fingerprint.

Cite this